REWRITING THE RULES OF DRUG CREATION
LIVE

Serial Number

97623507

Owner

Cellarity, Inc.

Attorney

Christina M. Licursi

Filing Date

Oct 7, 2022

Add to watchlist:

No watchlists yet
View on USPTO

REWRITING THE RULES OF DRUG CREATION Trademark

Serial Number: 97623507

REWRITING THE RULES OF DRUG CREATION is a trademark filed by Cellarity, Inc. on October 7, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Cellarity, Inc. (24 trademarks)

Somerville, MA 02143

Entity Type: 03

Trademark Details

Filing Date

October 7, 2022

Registration Date

Not Registered

Published for Opposition

March 26, 2024

Goods & Services

Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases

Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks

Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 5, 2026 EXRA
SOU EXTENSION 5 GRANTED
Aug 4, 2026 EX5G
SOU TEAS EXTENSION RECEIVED
Jul 29, 2026 EEXT
SOU EXTENSION 5 FILED
Jul 28, 2026 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 19, 2026 EXRA
SOU EXTENSION 4 GRANTED
May 18, 2026 EX4G
SOU EXTENSION 4 FILED
May 18, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
May 18, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 19, 2025 EXRA
SOU EXTENSION 3 GRANTED
Nov 18, 2025 EX3G
SOU EXTENSION 3 FILED
Nov 18, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 18, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2025 EXRA
SOU EXTENSION 2 GRANTED
May 17, 2025 EX2G
SOU EXTENSION 2 FILED
May 16, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
May 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 30, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 29, 2025 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 30, 2024 AITU
SOU EXTENSION 1 FILED
Nov 14, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 14, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 21, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 26, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 26, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 6, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 6, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 20, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 20, 2024 XAEC
ASSIGNED TO LIE
Feb 20, 2024 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 20, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 20, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 20, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 1, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 31, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 3, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 3, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 21, 2023 DOCK
TEAS VOLUNTARY AMENDMENT RECEIVED
Apr 6, 2023 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 31, 2022 NWOS